Keyphrases
Metastatic Melanoma
100%
T Cells
100%
Ipilimumab
100%
Tumor
100%
CTLA-4 Inhibitors
50%
Tumor Antigen
33%
Adoptive Cell Therapy
33%
Nave
33%
Advanced Melanoma
33%
Functional Properties
16%
Promising Treatment
16%
Previous Treatment
16%
Tumor-infiltrating Lymphocytes
16%
CD27
16%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
16%
Cellular Expression
16%
T Cell Specificity
16%
Anti-CTLA-4
16%
Phenotypic Markers
16%
T Cell Response
16%
Long-term Survival
16%
Medicine and Dentistry
Neoplasm
100%
Metastatic Melanoma
100%
T Cell
100%
Ipilimumab
100%
Cytotoxic T Lymphocyte Antigen 4 Antibody
50%
Tumor Antigen
33%
CTLA-4
33%
Cell Therapy
33%
Melanoma
33%
Long Term Survival
16%
T-Cell Response
16%
Cell Specificity
16%
Retrospective Study
16%
Tumor Infiltrating Lymphocyte
16%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Ipilimumab
100%
Neoplasm
100%
Melanoma
33%
Cytotoxic T Lymphocyte Antigen 4
33%
Tumor Antigen
33%
Retrospective Study
16%
Long Term Survival
16%
Immunology and Microbiology
Ipilimumab
100%
T Cell
100%
Cytotoxic T Lymphocyte Antigen 4 Antibody
50%
Tumor Antigen
33%
CTLA-4
33%
Long Term Survival
16%
Tumor-Associated Macrophage
16%
Cell Specificity
16%